HCM Valuation

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

HCM Relative Valuation

HCM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCM is overvalued; if below, it's undervalued.

Historical Valuation

HUTCHMED (China) Ltd (HCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.30 is considered Undervalued compared with the five-year average of 20.02. The fair price of HUTCHMED (China) Ltd (HCM) is between 20.08 to 46.91 according to relative valuation methord. Compared to the current price of 17.61 USD , HUTCHMED (China) Ltd is Undervalued By 12.31%.

Relative Value

Fair Zone

20.08-46.91

Current Price：17.61

12.31%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

19.81

P/B

Median3y

7.06

Median5y

6.49

-0.58

FCF Yield

Median3y

-3.08

Median5y

-3.78

Competitors Valuation Multiple

The average P/S ratio for HCM's competitors is 15.75, providing a benchmark for relative valuation. HUTCHMED (China) Ltd Corp (HCM) exhibits a P/S ratio of 4.30, which is -72.73% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap